All posts

BlackBerry has been our biggest dog, this fund manager says

With its share price continuing to trail off, it’s now a wait-and-see game for BlackBerry (BlackBerry News, Stock Quote, Chart TSX:BB), says portfolio manager Keith Richards, who claims the stock could plummet if it breaks through a key support level.

BlackBerry’s 2019 started off very well, with the stock gaining a full 40 per cent over the first three months, but since then it’s been mostly downhill, as all of those gains have now been erased and the stock looks about set to test a support level at C$9.00. Below that could be a significant plunge, says Richards of ValueTrend Wealth Management, who spoke to BNN Bloomberg on Tuesday.

“We own this stock, unfortunately. It’s been our single biggest dog,” Richards says. “There has been this really long, maybe five-year pattern but it is holding its last low.”

“It’s precarious. If it breaks, I will be out of the trade, but for now I’m in,” he says. “I’m underwater on it and I’m trying to be disciplined on this stuff. If it breaks, it breaks and I just say goodbye, but I’m giving it the benefit of the doubt because it has bounced off of these levels before. We’ll see what happens.”

BlackBerry has been roundly praised for its transformation from phone maker to software and security company but questions remain about revenue growth, with the company’s latest quarterly results coming as a prime example. While BB beat analysts’ estimates on adjusted revenue for its fiscal first quarter, coming in with a $267-million top line which was better than the expected $265 million, the company’s share price fell sharply with the quarterly release, nonetheless. (All figures in US dollars unless noted otherwise.)

The drop in share price was reportedly attributed to concerns over competition along with seemingly underwhelming results from Cylance, BlackBerry’s cybersecurity subsidiary, which brought in $32 million in GAAP revenue for the quarter.

More Cantech BlackBerry

Tagged with: bb
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Cannara Biotech is a buy, Research Capital says

Research Capital analyst Greg McLeish said in a July 29 update that Cannara Biotech (Cannara Biotech Stock Quote, Chart, News,… [Read More]

15 minutes ago

Ahead of Q2 results, is Tantalus Systems a buy?

Beacon Securities analyst Gabriel Leung noted in a July 30 report that Tantalus Systems (Tantalus Systems Holding Stock Quote, Chart,… [Read More]

29 minutes ago

Sanuwave Health is a buy, Roth Capital says

Roth Capital Markets is initiating coverage of Sanuwave Health (Sanuwave Health Stock Quote, Chart, News, Analysts, Financials NASDAQ:SNWV) with a… [Read More]

1 hour ago

Shoulder Innovations is an IPO to watch, this analyst says

Roth Capital Markets analyst Jason Wittes noted in a July 28 pre-IPO report that Shoulder Innovations, a new entrant in… [Read More]

1 hour ago

Nextracker wins price target raise at Roth

Roth Capital Markets analyst Philip Shen said in a July 28 earnings preview that Nextracker (Nextracker Stock Quote, Chart, News,… [Read More]

2 hours ago

Telus is my top telecom stock, Brian Madden says

Brian Madden, Chief Investment Officer at First Avenue Investment Counsel, said on BNN Bloomberg’s Market Call on July 25 that… [Read More]

22 hours ago